SMART Prices Act
- Bill Number
- S. 1836
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-05-21: Read twice and referred to the Committee on Finance.
- Last Updated
- 2025-06-02T14:26:58Z
AI-Generated Summary
Purpose
The Strengthening Medicare And Reducing Taxpayer Prices Act (SMART Prices Act) aims to enhance the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act (IRA). It seeks to lower prescription drug costs for Medicare beneficiaries by expanding the program's reach, accelerating drug eligibility for negotiation, and imposing stricter limits on negotiated prices, ultimately reducing taxpayer spending on Medicare.
Key Provisions
- Expansion of Negotiated Drugs: Starting in 2028 and beyond, the program will select 50 negotiation-eligible drugs annually, up from the previous limit of 15.
- Broader Drug Eligibility: The definition of a "qualifying single-source drug" (a drug without generic or biosimilar competition) is tightened by reducing the required market exclusivity period from 7 years (for small-molecule drugs) and 11 years (for biologics) to 3 years for both.
- Stricter Price Ceilings: The maximum fair price (the highest allowable negotiated price) for selected drugs is adjusted as follows:
- For drugs with average annual spending between $30 million and $75 million: ceiling raised slightly from 75% to 76% of the non-negotiated price.
- For drugs with spending between $75 million and $200 million: ceiling lowered from 65% to 55%.
- For drugs with spending over $200 million: ceiling lowered from 40% to 30%.
- Effective Date: These changes apply to price negotiations for initial applicability years starting in 2028.
Significant Changes to Existing Law
This bill amends sections 1192 and 1194 of the Social Security Act (title XVIII, which governs Medicare), building directly on the IRA's 2022 drug pricing reforms:
- Increases the scale of negotiations, removing prior caps on drug selection to allow more high-cost drugs to be targeted sooner.
- Shortens exclusivity protections, making more drugs eligible for negotiation earlier in their lifecycle (previously, drugs were protected longer to encourage innovation).
- Modifies price calculation formulas to enforce deeper discounts for higher-spending drugs, potentially leading to lower negotiated prices compared to the IRA's original ceilings.
Potential Impacts
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) will negotiate prices for more drugs, potentially saving billions in Medicare Part D expenditures and reducing federal budget deficits through lower reimbursements to pharmacies and plans.
- On Citizens: Medicare beneficiaries (primarily seniors and people with disabilities) could see reduced out-of-pocket costs for high-priced drugs, improving access to treatments for conditions like cancer or diabetes.
- On International Relations: Minimal direct impact, though lower U.S. drug prices might influence global pharmaceutical pricing strategies or trade discussions on intellectual property rights.
- Overall, the changes could accelerate cost savings estimated in the trillions over a decade but may increase administrative burdens on CMS.
Main Stakeholders Affected
- Medicare Beneficiaries: Primary beneficiaries of lower drug prices and premiums.
- Pharmaceutical Companies: Face reduced revenues from earlier and deeper price negotiations, potentially affecting R&D investments.
- Taxpayers and Government: Gain from fiscal savings in Medicare spending.
- Healthcare Providers and Insurers: Impacted indirectly through changes in drug reimbursement rates and formulary decisions.
- Generic and Biosimilar Manufacturers: May benefit from faster market entry due to shortened exclusivity periods.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill reinforces the IRA's framework, which has faced lawsuits from drug manufacturers claiming it violates constitutional protections (e.g., Takings Clause or due process). These changes could invite further challenges by intensifying price controls on intellectual property.
- Constitutional: No direct conflicts noted, but expansions of government negotiation power might raise Fifth Amendment concerns over "regulatory takings" of patent value.
- Political: Builds bipartisan support for drug pricing reform (introduced by a large Senate group) but could polarize debates on innovation incentives versus affordability, influencing future healthcare legislation and midterm election dynamics.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (26)
Sen. Welch, Peter [D-VT], Sen. Smith, Tina [D-MN], Sen. King, Angus S., Jr. [I-ME], Sen. Cantwell, Maria [D-WA], Sen. Reed, Jack [D-RI], Sen. Whitehouse, Sheldon [D-RI], Sen. Duckworth, Tammy [D-IL], Sen. Warren, Elizabeth [D-MA], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Merkley, Jeff [D-OR], Sen. Murray, Patty [D-WA], Sen. Blumenthal, Richard [D-CT], Sen. Shaheen, Jeanne [D-NH], Sen. Cortez Masto, Catherine [D-NV], Sen. Baldwin, Tammy [D-WI], Sen. Booker, Cory A. [D-NJ], Sen. Van Hollen, Chris [D-MD], Sen. Durbin, Richard J. [D-IL], Sen. Murphy, Christopher [D-CT], Sen. Fetterman, John [D-PA], Sen. Markey, Edward J. [D-MA], Sen. Luján, Ben Ray [D-NM], Sen. Hassan, Margaret Wood [D-NH], Sen. Heinrich, Martin [D-NM], Sen. Slotkin, Elissa [D-MI], Sen. Bennet, Michael F. [D-CO]
Recent Actions
- 2025-05-21: Read twice and referred to the Committee on Finance.
- 2025-05-21: Introduced in Senate
Bill Versions
- Strengthening Medicare And Reducing Taxpayer Prices Act — issued 2025-05-21 — PDF (3 pages)